

Date: 17 Jan 2024

Reference Number: SG-2401-415-H

قطاع الأجهزة والمستلزمات الطبية المركز الوطني لبلاغات الأجهزة والمستلزمات الطبية

Medical Devices Sector National Center for Medical Devices Reporting الهيئة الحامة للضذاء والحواء Saudi Food & Drug Authority

رسالة سلامة Safety Communication

To: Healthcare Provider		إلى: مقدمي الرعاية الصحية
Title	Recommendations for the safe and effective use of Acellular Dermal Matrix in Breast Reconstruction	المعنوان
Medical Device Description	Acellular Dermal Matrix	اسم ووصف الجهاز/المستلزم الطبي
Manufacturer	All	اسم المصنع
Authorized Representative	All	الممثل المعتمد
Medical Devices Marketing Authorization (MDMA)	All	إذن التسويق
Potential /Associated risks	As per the SFDA post-market clinical evaluation study, that analyze and evaluate the safe and effective use of Acellular Dermal Matrix (ADM) in Breast Reconstruction and how the ADM is being implanted after mastectomy. The study findings explicitly show that the use of ADM in breast reconstruction is associated with numerous complaints worldwide that shall be monitored, such as Seroma, Necrosis, Redbreast syndrome, and Wound healing issues. In addition, there is a potential risks due to an off-label use of certain ADM products that is not approved for breast reconstruction.	المخاطر المحتملة/ المرتبطة بالجهاز أو المستلزم الطبي
Recommendations	In order to reduce or eliminate the ADM associated complaints, here are some recommendations for healthcare providers: 1. Use ADM that have Medical Devices Marketing Authorization (MDMA) certificate from the SFDA. 2. Implant ADM that is authorized and labeled specifically for breast usage. 3. Do not use in breast reconstruction any ADM that is not approved for breast reconstruction since it is considered off-label use of medical devices. 4. Discuss with the patient all the potential benefits and risks of using ADM in breast reconstruction. 5. Follow manufacture recommendation for proper use of ADM. 6. Ensure to report any complaints/adverse events related to ADM to the SFDA through reporting channels.	التوصيات
For Reporting	SFDA 19999 NCMDR Oction line in the control of th	للإبلاغ

Code: MDS-F-310-020-V4